GLI-1 Antibody - BSA Free

Flow (Intracellular): GLI-1 Antibody - BSA Free [NB600-600]

Flow (Intracellular): GLI-1 Antibody [NB600-600] - Staining for GLI-1 in untreated human B cell lines (BCWM.1, MWCL-1 and RPCI-WM1) using anti-GLI-1 antibody. Rabbit IgG Isotype Control (Cat# NBP2-36463) was used as a negative control. Image courtesy of Sherine Elsawa, Northern Illinois University.

Immunohistochemistry-Paraffin: GLI-1 Antibody - BSA Free [NB600-600] -

Immunohistochemistry-Paraffin: GLI-1 Antibody - BSA Free [NB600-600] - Paracrine signaling of tumour-derived SHH in CAFs promotes lymphangiogenesis in vivo(A) Growth properties of subcutaneous tumours in mice derived from Caov3 SHH-OE or Caov3 NC cells alone or co-injected with CAFs. Kaplan-Meier plot of time to tumour progression, as evidenced by survival rates over time (n=5). (B) Bright field images of subcutaneous tumours from each group (n=5) 20 days after tumour implantation. (C) Graphical representation of the weights of subcutaneous tumours from each group 20 days after tumour implantation. (D) Immunohistochemical staining for Ki-67, alpha-SMA, Gli-1 & LYVE1 in tumour sections from mice in each group. (E) Graphical representation of the number of LYVE1+ vessels counted from IHC images in panel D. (*P<0.05, **P<0.01, ***P<0.001). Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.18621), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry-Paraffin: GLI-1 Antibody - BSA Free [NB600-600] -

Immunohistochemistry-Paraffin: GLI-1 Antibody - BSA Free [NB600-600] - Inhibition of Hh signaling in CAFs blocks its effects on lymphangiogenesis in vivo & in vitro(A) Representative images & statistical analyses of migration of LECs in a co-culture invasion system with CAFs stably transfected with shNC or Gli-shRNA lentivirus in the presence of rSHH (1 μg/ml). (B) Representative images & statistical analyses of capillary tube formation of LECs treated with supernatants from cultures of CAFs stably transfected with shNC or Gli-shRNA lentivirus in the presence of rSHH (1 μg/ml). (C) Bright field images & graphical representation of the weights of tumours of subcutaneous tumours from mice (n=5) bearing Caov3 SHH-OE cells co-injected with CAFs stably transfected with shNC or Gli-shRNA lentivirus 20 days after tumour implantation. (D) Growth properties of subcutaneous tumours in mice derived from Caov3 SHH-OE cells co-injected with CAFs stably transfected with shNC or Gli-shRNA lentivirus. Kaplan-Meier plot of time to tumour progression, as evidenced by survival rates over time. (E) IHC staining for Ki-67, alpha-SMA, Gli-1 & LYVE1 in tumour sections from mice in the two groups. (F) Graphical representation of the number of LYVE1+ vessels counted from IHC images in panel E. (**P<0.01, ***P<0.001). Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.18621), licensed under a CC-BY license. Not internally tested by Novus Biologicals.